Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aussie Biotechs Said To Suffer Double Effects Of Global Crisis

This article was originally published in PharmAsia News

Executive Summary

The Australian biotechnology industry is seeking government help to replace some of the investment money that has ceased to be available to them. The multibillion-dollar industry is dominated by successful giants, but 80 percent of the investment capital smaller companies need has dried up in the past year. AusBiotech, the association for Australia's biotech companies, also cites government policy that provides commercial grants only if they are matched by private investments. Unfortunately, the head of the group said, matching funds have dried up during the global financial crisis that continues. Even those that might have funds available to invest are reluctant to take a chance on them when government money is not available to help supplement a biotech's costs, she said. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel